Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE.

ABSTRACT: Screening initiatives for osteoporosis must facilitate treatment of those at elevated fracture risk. In a randomized controlled trial of 24,229 women, those in the screening group with FRAX ≥ 15% were invited for DXA with AOM treatment offered as per national guidelines. Treatment initiation in the following year was 9.5 times higher compared with controls.

Purpose

To determine if screened individuals have lower adherence to anti-osteoporotic medication (AOM) than unscreened and to examine determinants for low treatment adherence.

Method

In 2010/2011, women aged 65-80 (N = 34,229) in the Region of Southern Denmark were invited to the risk-stratified osteoporosis strategy evaluation (ROSE) randomized study. Women in the screening group with moderate to high 10-year fracture ri

SUBMITTER: Petersen TG 

PROVIDER: S-EPMC12064453 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature